RedHill Biopharma reported $2.69M in EBIT for its fiscal quarter ending in June of 2023.





Ebit Change Date
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
Cronos Group USD -1.45M 5.61M Mar/2026
RedHill Biopharma USD 2.69M 47.97M Jun/2023